Welcome to our dedicated page for QUALIS INNOVATIONS news (Ticker: QLIS), a resource for investors and traders seeking the latest updates and insights on QUALIS INNOVATIONS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QUALIS INNOVATIONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QUALIS INNOVATIONS's position in the market.
Qualis Innovations Inc. (QLIS) released its 10-Q report on November 14, 2022, highlighting total assets of approximately $453K and total debt under $84K. The company is advancing its SOLACE device aimed at non-drug pain management, with plans to submit a 510(k) application to the FDA in Q4 2022. The non-opioid pain treatment market is projected to grow to $78 billion by 2030. Qualis is also exploring an acquisition in opioid addiction solutions, which could significantly enhance its revenue potential. Management expresses confidence in achieving future growth amid the ongoing opioid crisis.
Qualis Innovations Inc. (QLIS) announced a $4 million Series A preferred stock offering aimed at accredited investors. The funds will support the development of its SOLACE device, a non-invasive medical technology designed to provide alternative pain management solutions using electromagnetic induction. The company plans to file its 510(k) application with the FDA by late 2022. This offering reflects Qualis Innovations' strategy to enhance its product portfolio and optimize market opportunities, while acknowledging the associated risks for potential investors.
Qualis Innovations Inc. (QLIS) will present at PAINWeek 2022, scheduled for September 6-9 in Las Vegas. CEO Dr. Joseph V. Pergolizzi, Jr. will discuss non-invasive devices targeting musculoskeletal pain conditions. The company is developing the SOLACE device, a non-invasive medical solution utilizing electromagnetic induction for pain relief. A 510(k) application to the FDA is expected by Q4 2022. Qualis aims to enhance its product portfolio through development and acquisitions in the pain management sector.
mPathix Health Inc., a subsidiary of Qualis Innovations Inc. (OTC: QLIS), has appointed James "Skip" Thurman as the new Sr. Vice President of Corporate and IR Communications. With a strong background in journalism and corporate communications, including a recent role at DaVita, Thurman is expected to enhance mPathix’s growth strategy. The company focuses on innovative pain management solutions and has a lead product, the SOLACE electromagnetic induction device, cleared by the FDA for specific medical conditions. This appointment signals a strategic move towards improved communication and market presence.
Qualis Innovations Inc. (OTC: QLIS) announced that Dr. Robert Bilkovski joined mPathix Health as Chief Scientific Officer on July 12, 2021. With extensive experience in medical devices and pharmaceuticals, Bilkovski is expected to enhance the company's clinical functions. His prior roles include leadership at Becton Dickinson, Abbott Labs, and GE Healthcare. mPathix focuses on developing multi-modal pain management solutions, including the SOLACE device, cleared by FDA for specific medical conditions.
Qualis Innovation Inc. has completed a share exchange agreement with mPathix Health Inc., making mPathix a wholly owned subsidiary of Qualis. This strategic move is expected to enhance Qualis's capabilities in developing treatments for central nervous system diseases. The new board of directors features well-respected professionals, including Demir Bingol as Chairman and CEO. mPathix focuses on multi-modal pain management solutions, with its leading product, the SOLACE device, already cleared by the FDA for specific medical conditions, excluding malignancies.
FAQ
What is the market cap of QUALIS INNOVATIONS (QLIS)?
